

Robert C Stein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8602666/publications.pdf>

Version: 2024-02-01

92
papers

6,554
citations

76326

40
h-index

74163

75
g-index

95
all docs

95
docs citations

95
times ranked

8377
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative survival analysis of multiparametric tests when molecular tests disagree A TEAM Pathology study. <i>Npj Breast Cancer</i> , 2021, 7, 90.	5.2	0
2	Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 423-433.	1.6	240
3	Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training. <i>PLoS ONE</i> , 2020, 15, e0238593.	2.5	2
4	Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer. , 2020, , .		0
5	Hyperpolarised ¹³ C MRI: a new horizon for non-invasive diagnosis of aggressive breast cancer. <i>BJR case Reports</i> , 2019, 5, 20190026.	0.2	7
6	Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor Positive Early Breast Cancer: PALLET Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 178-189.	1.6	136
7	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 108-120.	5.0	49
8	Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. <i>Health Technology Assessment</i> , 2019, 23, 1-328.	2.8	35
9	An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. <i>Journal of Clinical Epidemiology</i> , 2018, 99, 75-83.	5.0	25
10	OP66 Tumor Profiling Tests In Early Breast Cancer: A Systematic Review. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 24-24.	0.5	0
11	Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework. <i>Trials</i> , 2018, 19, 50.	1.6	48
12	AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1007-1007.	1.6	51
13	Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. <i>British Journal of Cancer</i> , 2017, 116, 859-863.	6.4	9
14	IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 343-353.	2.5	43
15	Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 929-945.	10.7	58
16	Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. <i>Value in Health</i> , 2017, 20, 1311-1318.	0.3	31
17	Informed consent in randomised controlled trials: development and preliminary evaluation of a measure of Participatory and Informed Consent (PIC). <i>Trials</i> , 2017, 18, 327.	1.6	9
18	Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians Practices across Six Randomised Controlled Trials. <i>PLoS Medicine</i> , 2016, 13, e1002147.	8.4	82

#	ARTICLE	IF	CITATIONS
19	Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it right. <i>European Journal of Surgical Oncology</i> , 2016, 42, 994-998.	1.0	6
20	OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions. <i>European Journal of Surgical Oncology</i> , 2016, 42, S9-S10.	1.0	0
21	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw050.	6.3	166
22	Abstract OT1-03-13: A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC)(NCT02423603)., 2016, , .		3
23	Abstract OT3-02-02: ROSCO: A randomised phase III, stratified CEP17/TOP2A biomarker trial of neo-adjuvant 5-flourouracil, epirubicin and cyclophosphamide vs docetaxel and cyclophosphamide chemotherapy. , 2016, , .		1
24	A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) – Trial Results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 549-549.	1.6	5
25	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-202.	2.8	53
26	Abstract OT3-02-12: OPTIMA (optimal personalised treatment of early breast cancer using) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td of gene expression test-directed chemotherapy decisions. , 2016, , .		0
27	Abstract PD2-02: NEO-EXCEL phase III neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER positive postmenopausal early breast cancer. , 2016, , .		1
28	OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS623-TPS623.	1.6	4
29	The use of early decision modelling and value of information analysis in an adaptive trial design: results from the OPTIMA preliminary study. <i>Trials</i> , 2015, 16, .	1.6	0
30	1809 Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer using) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302 Td	2.8	1
31	Practicalities of using an adaptive design for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests. <i>Trials</i> , 2015, 16, .	1.6	0
32	Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. <i>Histopathology</i> , 2015, 67, 279-293.	2.9	26
33	Abstract P4-11-07: Comparison of multiparameter tests in the UK OPTIMA-Prelim trial. , 2015, , .		4
34	Abstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer. , 2015, , .		0
35	HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice. <i>Journal of Clinical Pathology</i> , 2014, 67, 161-167.	2.0	15
36	Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. <i>British Journal of Cancer</i> , 2014, 110, 1950-1957.	6.4	15

#	ARTICLE	IF	CITATIONS
37	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	5.0	320
38	Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial. <i>Clinical Oncology</i> , 2013, 25, 109-116.	1.4	37
39	Efficient design of a phase III trial of competing tests for personalised cancer treatment in the absence of gold standard outcome data: challenges and potential solutions. <i>Trials</i> , 2013, 14, .	1.6	1
40	Using adaptive designs for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests. <i>Trials</i> , 2013, 14, O12.	1.6	0
41	An adaptive biomarker strategy clinical trial design. <i>Trials</i> , 2013, 14, .	1.6	0
42	Economic Evaluation of Genomic Testâ€œDirected Chemotherapy for Early-Stage Lymph Nodeâ€œPositive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 56-66.	6.3	75
43	Functional Proteomic Analysis of Long-term Growth Factor Stimulation and Receptor Tyrosine Kinase Coactivation in Swiss 3T3 Fibroblasts. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 1690-1708.	3.8	3
44	Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). , 2012, , .		5
45	Trastuzumab beyond progression: Overall survival analysis of the GBC 26/BIG 3-05 phase III study in HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2011, 47, 2273-2281.	2.8	164
46	Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2â€œPositive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1999-2006.	1.6	685
47	The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. <i>Oncogene</i> , 2009, 28, 4041-4052.	5.9	74
48	Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin. <i>Cancer Research</i> , 2007, 67, 3239-3253.	0.9	135
49	Predictors of ovarian reserve in young women with breast cancer. <i>British Journal of Cancer</i> , 2007, 96, 1808-1816.	6.4	129
50	A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. <i>British Journal of Cancer</i> , 2006, 94, 828-834.	6.4	349
51	Tumour-Stromal Interactions in Breast Cancer: The Role of Stroma in Tumorigenesis. <i>Tumor Biology</i> , 2005, 26, 173-185.	1.8	95
52	Three-dimensional in vitro tissue culture models of breast cancer â€œ a review. <i>Breast Cancer Research and Treatment</i> , 2004, 85, 281-291.	2.5	268
53	Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation. <i>EMBO Journal</i> , 2003, 22, 4178-4189.	7.8	139
54	Models of breast cancer: is merging human and animal models the future?. <i>Breast Cancer Research</i> , 2003, 6, 22-30.	5.0	63

#	ARTICLE	IF	CITATIONS
55	Activation of the ATPase Activity of Hsp90 by the Stress-Regulated Cochaperone Aha1. <i>Molecular Cell</i> , 2002, 10, 1307-1318.	9.7	487
56	Cluster analysis of an extensive human breast cancer cell line protein expression map database. <i>Proteomics</i> , 2002, 2, 212-223.	2.2	48
57	Combinatorial use of mRNA and two-dimensional electrophoresis expression data to choose relevant features for mass spectrometric identification. <i>Proteomics</i> , 2002, 2, 1464-1473.	2.2	5
58	The application of 2D gel-based proteomics methods to the study of breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2002, 7, 385-393.	2.7	26
59	Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.. <i>Endocrine-Related Cancer</i> , 2001, 8, 237-248.	3.1	115
60	Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. <i>Biochemical Journal</i> , 2000, 348, 351.	3.7	20
61	Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. <i>Biochemical Journal</i> , 2000, 348, 351-358.	3.7	69
62	PI3-kinase inhibition: a target for drug development?. <i>Trends in Molecular Medicine</i> , 2000, 6, 347-358.	2.6	184
63	Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 12589-12594.	7.1	219
64	Solution structure of the C-terminal SH2 domain of the p85 β regulatory subunit of phosphoinositide 3-kinase 1 1 Edited by P. E. Wright. <i>Journal of Molecular Biology</i> , 1998, 276, 461-478.	4.2	50
65	Human Phosphoinositide 3-Kinase C2 β , the Role of Calcium and the C2 Domain in Enzyme Activity. <i>Journal of Biological Chemistry</i> , 1998, 273, 33082-33090.	3.4	116
66	SH2 and SH3 Domains: Unraveling Signaling Networks with Peptide Antagonists. , 1998, 88, 187-196.		5
67	Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. <i>Biochemical Journal</i> , 1997, 326, 139-147.	3.7	228
68	p110 β , a novel phosphoinositide 3-kinase in leukocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 4330-4335.	7.1	403
69	Assessment of response to treatment during chemotherapy for breast cancer. A new role for breast MRI?. <i>Breast</i> , 1997, 6, 319-320.	2.2	0
70	Structural and functional diversity of phosphoinositide 3-kinases. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1996, 351, 217-223.	4.0	91
71	A phase II study of ifosfamide and bleomycin in advanced or recurrent cervical carcinoma. <i>International Journal of Gynecological Cancer</i> , 1996, 6, 323-327.	2.5	1
72	Immunomodulatory agents: the cytokines. <i>European Journal of Cancer</i> , 1994, 30, 400-404.	2.8	7

#	ARTICLE	IF	CITATIONS
73	A randomised prospective trial of surgical against medical tetracycline pleurodesis in the management of malignant pleural effusions secondary to breast cancer. <i>European Journal of Cancer</i> , 1993, 29, 316-319.	2.8	29
74	A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. <i>British Journal of Cancer</i> , 1993, 68, 1190-1194.	6.4	8
75	A double-blind study of the efficacy of metronidazole gel in the treatment of malodorous fungating tumours. <i>European Journal of Cancer</i> , 1992, 28, 888-889.	2.8	58
76	An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. <i>European Journal of Cancer</i> , 1992, 28, 415-420.	2.8	37
77	Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial. <i>European Journal of Cancer</i> , 1992, 28, 1963-1965.	2.8	10
78	Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1992, 43, 155-159.	2.5	79
79	A preliminary clinical study of gossypol in advanced human cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 480-482.	2.3	90
80	Lactic acidosis. A presentation of metastatic breast cancer arising in pregnancy. <i>Cancer</i> , 1992, 69, 453-456.	4.1	21
81	Clinical oncology: Case presentations from oncology centres 1. Ewing's sarcoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1525-1533.	0.7	3
82	Topical calcipotriol treatment in advanced breast cancer. <i>Lancet</i> , The, 1991, 337, 701-702.	13.7	109
83	Comparison of ondansetron with dexamethasone and domperidone in the prophylaxis of non-cisplatin chemotherapy induced emesis refractory to dexamethasone. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 302-303.	0.7	3
84	The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2. <i>British Journal of Cancer</i> , 1991, 63, 275-278.	6.4	64
85	Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 27, 367-372.	2.3	28
86	The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. <i>British Journal of Cancer</i> , 1990, 62, 679-683.	6.4	96
87	Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study. <i>British Journal of Cancer</i> , 1990, 61, 451-453.	6.4	23
88	POTENCY AND SELECTIVITY OF THE NON-STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTS. <i>Clinical Endocrinology</i> , 1990, 32, 623-634.	2.4	82
89	Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 75-78.	2.3	52
90	Analysis of Gossypol Enantiomers in Human Serum. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1990, 13, 2261-2268.	1.0	4

#	ARTICLE	IF	CITATIONS
91	Epirubicin for pretreated advanced ovarian cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1990, 26, 850-851.	0.7	16
92	Nonmetastatic manifestations of malignancy: hormonal. <i>Palliative Medicine</i> , 1989, 3, 189-196.	3.1	1